7-Hydroxy-3,4-dihydro-2(1H)-quinolinone, with the CAS number 22246-18-0, is a natural organic substance that has been discovered to show promising activity in the field of anti-tumor drugs. It is a quinoline derivative that acts as a selective inhibitor of topoisomerase I, an enzyme that plays an important role in DNA replication, recombination, and transcription. Through its inhibition of topoisomerase I, which is overexpressed in some cancer cells, 7-Hydroxy-3,4-dihydro-2(1H)-quinolinone has shown to effectively block DNA synthesis and cause cell death in cancer cells. In addition to its potential use as an anti-tumor drug, research has also shown that 7-Hydroxy-3,4-dihydro-2(1H)-quinolinone has other properties that make it appealing for development as a therapeutic compound. Studies have found that it possesses anti-inflammatory effects and can act as an antioxidant. These properties suggest that it may also have the potential to be used as a treatment for various chronic inflammatory diseases. Overall, with its unique structure and promising activity in various applications, 7-Hydroxy-3,4-dihydro-2(1H)-quinolinone shows significant potential as an active pharmaceutical ingredient in various fields of medicine, including oncology and inflammatory diseases. Research continues to explore its potential benefits and effectiveness as a therapeutic compound.

Ruifu Chemical Becomes Leading Supplier of API and Pharmaceutical Intermediates Ruifu Chemical, a leading supplier of API, pharmaceutical intermediates, chiral compounds, and amino acids, has continu

Ruifu Chemical Emerges as a Leading Supplier of High-quality API, Pharmaceutical Intermediates, and Amino Acids Ruifu Chemical, a leading supplier of API, pharmaceutical intermediates, chiral compoun

RUIFU CHEMICAL: A LEADING SUPPLIER OF HIGH-QUALITY API AND INTERMEDIATES Ruifu Chemical has emerged as a leading supplier of API, pharmaceutical intermediates, chiral compounds, and amino acids since